Table 3 Clinical application of EBV DNA in T cell lymphoma
From: Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
Lymphoma subtypes | Author | PMID/doi | Biomarker | Liquid Biopsy | Method | No. of patients | Results | Clinical applications |
|---|---|---|---|---|---|---|---|---|
ENKTL | Lei, Kenny I K et al. [132] | 11801537 | EBV DNA levels | PB | qRT-PCR | 18 | plasma EBV DNA was detected in 17/18 patients but in 0/35 control subjects (P < 0.0001) Clinically responding patients plasma EBV DNA levels fall whereas no responding patients rapid increase patients baseline plasma EBV DNA levels ≥ 600 copies/ml vs < 600 copies/ml, OS 21% vs 78%; P = 0.024 | diagnosis, prognosis. longitudinal monitoring |
ENKTL, nTFHL-AI | Au, Wing-Yan et al. [133] | 15031209 | EBV DNA levels | PB | Q-PCR | 39 | high-presentation EBV DNA (> 6.1 × 107 copies/mL) was significantly associated with an inferior DFS. During treatment, patients with EBV DNA had significantly inferior OS | diagnosis, prognosis. longitudinal monitoring |
ENKTL | Kwong YL et al. [134] | 23842425 | EBV DNA levels | PB | Q-PCR | 56 | negative EBV DNA after SMILE had the most significant impact (P < 0.001) on OS and persistently undetectable EBV DNA had the most significant impact (P = 0.002) on DFS | prognosis |
ENKTL | Wang XX et al. [135] | 30646796 | EBV DNA levels | PB | qRT-PCR | 99 | 3-year OS: pre-, interim-, post-treatment EBV-DNA, positive vs negative, 70.2% vs. 93.9% (P = 0.022), 53.8% vs. 99.1% (P < 0.001), 40.6% vs. 91.8% (P < 0.001) | prognosis. longitudinal monitoring |
PTCL, NOS, ALCL, nTFHL-AI | Zhao D et al. [136] | 34753127 | EBV DNA levels | PB | qRT-PCR | 128 | pre-treatment EBV-DNA ≥ 500 copies/mL(3-year PFS: 12.2% vs. 48.2%, p = 0.001; 3-year OS: 42.5% vs. 66.1%, P = 0.003) EBV-DNA with normalization of after first-line chemotherapy ORR (81.3% vs. 22.2%, P = 0.014), PFS (12.0 m vs. 3.7 m, P = 0.011), OS (37.9 m vs. 7.8 m, P = 0.012) | prognosis. longitudinal monitoring |
PTCL, NOS, nTFHL-AI, ENKTL | Suwiwat, Supaporn et al. [137] | 17996493 | EBV DNA levels | PB | RT-PCR | 45 | concentration of EBV DNA in the plasma was not a prognostic marker in PTCL and PTPD patients | prognosis |
nTFHL-AI | Delfau-Larue, MH et al. [138] | 22371178 | EBV DNA levels | PB | RT-PCR | 25 | peripheral EBV load at diagnosis (≥ 100 copy/μg DNA) was associated with shorter PFS (P = 0.06) | prognosis |
ENKTL | Wang ZY et al. [139] | 22826562 | EBV DNA levels | PB | RT-PCR | 69 | 3-year OS and PFS rates: pretreatment EBV-DNA level of ≤ 500 copies/mL vs > 500 copies/mL, 97.1% and 79.0% vs 66.3% (P = .002) and 52.2% (P = .045) | prognosis |
ENKTL | Wang L et al. [140] | 26210287 | EBV DNA levels | PB | qRT-PCR | 68 | Patients with negative pretreatment EBV-DNA had a higher CR rate (96.0% vs. 69.8%, P = 0.023) post-treatment EBV-DNA positivity and treatment response (non-CR) were prognostic factors for both worse PFS and OS (P < 0.05) | prognosis MRD |